ASCO GU 2018: Evaluation of prostate cancer risk in men with PSA 1.5

San Francisco, CA (UroToday.com) There is growing evidence that genomic classification of malignancies, including prostate cancer, may help overcome the heterogeneity and inherent subjective flaws of clinical staging systems. Genomic tests for prostate cancer abound, with many addressing PCa in its various clinical stages. Some are based on prostate biopsy tissue, while others are based on prostatectomy or metastatectomy specimens.

ASCO GU 2018: Impact of Genomic Risk Scores on Treatment Decisions Following Radical Prostatectomy in a Prospective Medicare Registry

San Francisco, CA (UroToday.com) There is growing evidence that genomic classification of malignancies, including prostate cancer, may help overcome the heterogeneity and inherent subjective flaws of clinical staging systems. There are many genomic tests for prostate cancer that address prostate cancer in its various clinical stages. Some are based on prostate biopsy tissue, while others are based on prostatectomy or metastatectomy specimens.   

ASCO GU 2018: Adjuvant Enzalutamide (ENZA) for Men with Non-metastatic High-risk Prostate Cancer (HRPCa) After Radical Prostatectomy (RP).

San Francisco, CA (UroToday.com) In this novel study, the authors assess the utility of an oral androgen-axis inhibitor, enzalutamide, as an adjuvant therapy for men with high-risk localized PCa following definitive RP. In this setting, radiotherapy, either adjuvant or salvage, remains the standard of care – though not without significant morbidity.

ASCO GU 2018: Lu-177-labeled PSMA-I&T Radioligand Therapy for mCRPC

San Francisco, CA (UroToday.com) The authors of this study aimed to report their clinical experience with 177Lutetium-labeled prostate-specific membrane antigen-ligand (177Lu-PSMA-I&T) for systemic radioligand therapy in 100 consecutive patients with metastatic castration-resistant prostate cancer (mCRPC).

ASCO GU 2018: Daily Versus Weekly Prostate Cancer image-guided Radiotherapy: A Phase 3, Multi-center, Randomized Trial

San Francisco, CA (UroToday.com) As part of the prostate cancer rapid-fire abstract session, Dr. Renaud de Crevoisier presented data from his multi-center study evaluating the optimal frequency of obtaining planning imaging when treating prostate cancer patients with image-guided radiation therapy (IGRT).

ASCO GU 2018: Comparison of Enzalutamide and Bicalutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer - STRIVE Study

San Francisco, CA (UroToday.com) Androgen receptor inhibitors enzalutamide (ENZA) and bicalutamide (BIC) are used to treat metastatic castration-resistant prostate cancer (mCRPC). The Phase 2 STRIVE trial included 35% non-metastatic (m0) and 65% metastatic CRPC patients. ENZA reduced the risk of progression or death among pts, with an adverse event profile consistent with previous trials.

ASCO GU 2018: Treatment Duration And Utilization Patterns In Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide or Abiraterone Acetate

San Francisco, CA (UroToday.com) Enzalutamide (ENZA) and abiraterone acetate (ABI) are approved hormonal therapies for men with metastatic castration-resistant prostate cancer (mCRPC). The authors presented a study assessing the real-world treatment duration and utilization patterns in patients receiving ENZA or ABI.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe